DK1641764T3 - P38-kinasehæmmere på grundlag af 5-leddede heterocykliske forbindelser - Google Patents

P38-kinasehæmmere på grundlag af 5-leddede heterocykliske forbindelser

Info

Publication number: DK1641764T3
Authority: DK; Denmark
Prior art keywords: basis; kinase inhibitors; kinase; membered heterocyclic; heterocyclic compounds
Prior art date: 2003-06-26

Application number

DK04777075.5T

Other languages

English (en)

Inventor

Olga M Fryszman

Hengyuan Lang

Jiong Lan

Edcon Chang

Yunfeng Fang

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-26

Filing date

2004-06-24

Publication date

2011-11-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34108816&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1641764(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-06-24 Application filed by Novartis Ag filed Critical Novartis Ag

2011-11-21 Application granted granted Critical

2011-11-21 Publication of DK1641764T3 publication Critical patent/DK1641764T3/da

Links

229940043355 kinase inhibitor Drugs 0.000 title abstract 2
239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 2
150000000565 5-membered heterocyclic compounds Chemical class 0.000 title 1
102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 abstract 4
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 3
150000001875 compounds Chemical class 0.000 abstract 2
208000027866 inflammatory disease Diseases 0.000 abstract 2
102000001253 Protein Kinase Human genes 0.000 abstract 1
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 abstract 1
208000037765 diseases and disorders Diseases 0.000 abstract 1
125000000623 heterocyclic group Chemical group 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
108060006633 protein kinase Proteins 0.000 abstract 1
208000024891 symptom Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C07D231/52—Oxygen atom in position 3 and nitrogen atom in position 5, or vice versa
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Neurology (AREA)
Immunology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Tropical Medicine & Parasitology (AREA)
Pain & Pain Management (AREA)
Biotechnology (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Gastroenterology & Hepatology (AREA)
Vascular Medicine (AREA)

DK04777075.5T 2003-06-26 2004-06-24 P38-kinasehæmmere på grundlag af 5-leddede heterocykliske forbindelser DK1641764T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US48342803P	2003-06-26	2003-06-26
US49905403P	2003-08-29	2003-08-29
US56048104P	2004-04-07	2004-04-07
PCT/US2004/020384 WO2005009973A1 (en)	2003-06-26	2004-06-24	5-membered heterocycle-based p38 kinase inhibitors

Publications (1)

Publication Number	Publication Date
DK1641764T3 true DK1641764T3 (da)	2011-11-21

Family

ID=34108816

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK04777075.5T DK1641764T3 (da)	2003-06-26	2004-06-24	P38-kinasehæmmere på grundlag af 5-leddede heterocykliske forbindelser
DK10164367.4T DK2298743T3 (da)	2003-06-26	2004-06-24	p38-Kinaseinhibitorer på grundlag af en 5-leddet heterocyclisk ring

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK10164367.4T DK2298743T3 (da)	2003-06-26	2004-06-24	p38-Kinaseinhibitorer på grundlag af en 5-leddet heterocyclisk ring

Country Status (26)

Country	Link
US (4)	US7863314B2 (da)
EP (2)	EP1641764B1 (da)
JP (1)	JP4838121B2 (da)
KR (1)	KR101120857B1 (da)
CN (1)	CN1832928B (da)
AT (1)	ATE517872T1 (da)
AU (1)	AU2004259662B2 (da)
BR (1)	BRPI0411825B8 (da)
CA (1)	CA2526455C (da)
CY (2)	CY1111985T1 (da)
DK (2)	DK1641764T3 (da)
EC (2)	ECSP056206A (da)
ES (1)	ES2393950T3 (da)
HR (2)	HRP20110757T1 (da)
IL (1)	IL172182A (da)
IS (2)	IS2916B (da)
MA (1)	MA27888A1 (da)
MX (1)	MXPA05013824A (da)
MY (1)	MY158162A (da)
NO (1)	NO334947B1 (da)
NZ (1)	NZ544230A (da)
PL (2)	PL1641764T3 (da)
PT (2)	PT2298743E (da)
SI (2)	SI2298743T1 (da)
TW (2)	TWI449696B (da)
WO (1)	WO2005009973A1 (da)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7485657B2 (en)	2004-05-12	2009-02-03	Boehringer Ingelheim Pharmaceuticals, Inc.	Anti-cytokine heterocyclic compounds
JP2008539276A (ja) *	2005-04-27	2008-11-13	ユニバーシティオブフロリダリサーチファウンデーション，インコーポレイティド	ヒト疾患に関連する変異体タンパク質の分解能を改善するための材料及び方法
DE102005031580A1 (de) *	2005-07-06	2007-01-11	Aicuris Gmbh & Co. Kg	Substituierte Sulfolanylpyrazole und ihre Verwendung
GB0603684D0 (en) *	2006-02-23	2006-04-05	Novartis Ag	Organic compounds
CN101405270B (zh)	2006-03-22	2013-01-16	霍夫曼-拉罗奇有限公司	作为11-β-HSD-1的吡唑类
EP2035038A4 (en) *	2006-04-03	2011-04-06	Stowers Inst For Medical Res	COMPOSITIONS AND METHODS FOR TREATING POLYCYSTIC KIDNEY DISEASE
WO2008052974A1 (en) *	2006-10-30	2008-05-08	Novartis Ag	3-amino-pyrazole-4-carboxamide derivatives useful as inhibitors of protein kinases
GB0621978D0 (en) *	2006-11-03	2006-12-13	Chroma Therapeutics Ltd	Inhibitors of p38 mitogen-activated protein kinase
EP1992344A1 (en)	2007-05-18	2008-11-19	Institut Curie	P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
EP2178370A4 (en) *	2007-07-17	2011-01-12	Zalicus Inc	COMBINATIONS FOR THE TREATMENT OF PROLIFERATIVE B-CELL DISEASES
WO2009011893A2 (en) *	2007-07-17	2009-01-22	Combinatorx, Incorporated	Treatments of b-cell proliferative disorders
CN101711245B (zh)	2007-07-19	2015-03-25	H.隆德贝克有限公司	5元杂环酰胺及相关的化合物
US8119800B2 (en) *	2007-12-21	2012-02-21	Korea Research Institute Of Chemical Technology	Processes for preparing HIV reverse transcriptase inhibitors
DE102008015033A1 (de) *	2008-03-17	2009-09-24	Aicuris Gmbh & Co. Kg	Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
US20090281150A1 (en) *	2008-04-09	2009-11-12	Nicola Frances Bateman	Compound 249
WO2009151569A2 (en) *	2008-06-09	2009-12-17	Combinatorx, Incorporated	Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
CA2732437C (en)	2008-08-01	2017-11-21	Ventirx Pharmaceuticals, Inc.	Toll-like receptor agonist formulations and their use
ES2545275T3 (es)	2008-11-06	2015-09-09	Ventirx Pharmaceuticals, Inc.	Métodos de síntesis de derivados de benzazepinas
HRP20151258T1 (hr)	2009-08-07	2016-02-26	Chugai Seiyaku Kabushiki Kaisha	Derivat aminopirazola
CN105669552A (zh)	2009-08-18	2016-06-15	文蒂雷克斯药品公司	作为toll样受体调节剂的取代的苯并氮杂*
CN105669553A (zh)	2009-08-18	2016-06-15	文蒂雷克斯药品公司	作为toll样受体调节剂的取代的苯并氮杂*
WO2011038261A1 (en) *	2009-09-24	2011-03-31	Selexagen Therapeutics, Inc.	Heterocyclic kinase inhibitors
WO2011100769A2 (en) *	2010-02-15	2011-08-18	Synovo Gmbh	Kinase modulators for the treatment of cancer
WO2012039972A1 (en) *	2010-09-21	2012-03-29	Eisai R&D Management Co., Ltd.	Pharmaceutical composition
US8993631B2 (en)	2010-11-16	2015-03-31	Novartis Ag	Method of treating contrast-induced nephropathy
EP2460519A1 (en) *	2010-12-03	2012-06-06	Laboratorios Del. Dr. Esteve, S.A.	Use of sigma ligands in bone cancer pain
JP5620417B2 (ja) *	2011-02-07	2014-11-05	中外製薬株式会社	アミノピラゾール誘導体を含む医薬
ES2605942T3 (es) *	2012-03-20	2017-03-17	Mereo Biopharma 1 Limited	Uso de un derivado de pirazol en el tratamiento de exacerbaciones agudas de enfermedad pulmonar obstructiva crónica
WO2015084936A1 (en) *	2013-12-04	2015-06-11	The Scripps Research Institute	Novel compounds as jnk kinase inhibitors
US9624201B2 (en)	2013-12-13	2017-04-18	Hoffmann-La Roche Inc.	Inhibitors of bruton's tyrosine kinase
KR101822767B1 (ko)	2013-12-13	2018-01-26	에프. 호프만-라 로슈 아게	브루톤 티로신 키나아제의 억제제
WO2015099127A1 (ja)	2013-12-27	2015-07-02	中外製薬株式会社	Ｆｇｆｒゲートキーパー変異遺伝子およびそれを標的とする医薬
JP6762300B2 (ja)	2015-06-17	2020-09-30	中外製薬株式会社	アミノピラゾール誘導体
CN107406431B (zh) *	2015-08-20	2020-06-26	上海昂睿医药技术有限公司	吲哚类衍生物及其制备方法和其在医药上的用途
WO2017153702A1 (en)	2016-03-08	2017-09-14	Mereo Biopharma 1 Limited	Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease
US10617674B2 (en)	2016-03-08	2020-04-14	Mereo Biopharma 1 Limited	Dosage regimen for the treatment of acute exacerbations of inflammatory conditions
GB201612238D0 (en) *	2016-07-14	2016-08-31	Mereo Biopharma 1 Ltd	Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-Yl]-n-cyclopropyl-4-methylbenzamide
GB201612240D0 (en) *	2016-07-14	2016-08-31	Mereo Biopharma 1 Ltd	Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide
WO2018059533A1 (zh) *	2016-09-29	2018-04-05	南京明德新药研发股份有限公司	p38αMAPK激酶抑制剂及其制备方法和应用
ES2952744T3 (es)	2016-12-15	2023-11-03	Nestle Sa	Composiciones y procedimientos que modulan los glóbulos blancos o los neutrófilos en un animal de compañía
ES2927715T3 (es)	2017-10-05	2022-11-10	Fulcrum Therapeutics Inc	Inhibidores de la quinasa p38 reducen la expresión de dux4 y de los genes que le siguen para el tratamiento de la FSHD
KR102899004B1 (ko)	2017-12-11	2025-12-12	메레오 바이오파마 1 리미티드	만성 폐쇄성 폐 질환의 급성 악화의 치료에서의 3-[5-아미노-4-(3-시아노벤조일)-피라졸-1-일]-n-시클로프로필-4-메틸벤즈아미드의 용도
HUE054266T2 (hu)	2017-12-11	2021-08-30	Mereo Biopharma 1 Ltd	3-[5-amino-4-(3-cianobenzoil)-pirazol-1-il]-N-ciklopropil-4-metilbenzamid alkalmazása krónikus obstruktív tüdõbetegség akut megjelenésének megelõzésében
EP3773579A4 (en)	2018-03-26	2022-03-09	Clear Creek Bio, Inc.	COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE
EP3563848A1 (en) *	2018-04-30	2019-11-06	S.I.S.S.A. Scuola Internazionale Superiore di Studi Avanzati	Serpin inhibitors for the treatment of prion and prion-like diseases
GB201815696D0 (en)	2018-09-26	2018-11-07	Mereo Biopharma 1 Ltd	Synthetic method
GB201815699D0 (en) *	2018-09-26	2018-11-07	Mereo Biopharma 1 Ltd	Synthetic method
GB201815695D0 (en) *	2018-09-26	2018-11-07	Mereo Biopharma 1 Ltd	Synthetic method
CN110950848B (zh) *	2018-09-27	2024-03-26	徐诺药业	新型氨基吡唑类衍生物的合成与应用
CN113015730A (zh) *	2018-11-13	2021-06-22	诺华股份有限公司	用于治疗与nlrp活性相关的病症的化合物和组合物
CN113166081A (zh)	2018-11-13	2021-07-23	诺华股份有限公司	用于治疗与nlrp活性相关的病症的化合物和组合物
US12076315B2 (en)	2020-03-20	2024-09-03	Clear Creek Bio, Inc.	Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof
CN112778333B (zh) *	2021-01-23	2022-07-05	中国科学院新疆理化技术研究所	一种四氢噁唑并吡啶并氮氧杂酮类衍生物及其用途
WO2026011033A1 (en) *	2024-07-03	2026-01-08	Empire Discovery Institute	P38gamma inhibitors and methods of use thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1152421B (de)	1961-03-21	1963-08-08	Bayer Ag	Verfahren zur Herstellung von 4-Hydroxy-pyrazolo[3, 4-b]chinolinen
JPS5111499Y2 (da)	1971-04-22	1976-03-27
USRE28819E (en)	1972-12-08	1976-05-18	Syntex (U.S.A.) Inc.	Dialkylated glycol compositions and medicament preparations containing same
JPS5527916B2 (da)	1973-02-05	1980-07-24
JPS51112341A (en)	1975-02-24	1976-10-04	Konishiroku Photo Ind Co Ltd	Magenta dye image formation
US4200750A (en)	1977-01-07	1980-04-29	Westwood Pharmaceuticals Inc.	4-Substituted imidazo [1,2-a]quinoxalines
US6103900A (en)	1992-12-17	2000-08-15	Pfizer Inc	Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
US6005109A (en)	1997-10-30	1999-12-21	Pflizer Inc.	Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
DK0674624T3 (da)	1992-12-17	1999-09-13	Pfizer	Pyrazoler med CRF-antagonistisk aktivitet
US5514643A (en)	1993-08-16	1996-05-07	Lucky Ltd.	2-aminothiazolecarboxamide derivatives, processes for preparing the same and use thereof for controlling phytopathogenic organisms
US5646152A (en)	1994-06-15	1997-07-08	Pfizer Inc.	Methods of administering CRF antagonists
CA2163399A1 (en)	1994-11-24	1996-05-25	Katsuhiro Kawano	Triazine derivative, chymase activity inhibitor and nitric oxide production inhibitor
DE19518054A1 (de)	1995-03-08	1996-09-12	Hoechst Schering Agrevo Gmbh	N-Arylpyrazolketone und deren Derivate, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel
IL118544A (en)	1995-06-07	2001-08-08	Smithkline Beecham Corp	History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
US5756499A (en)	1996-01-11	1998-05-26	Smithkline Beecham Corporation	Substituted imidazole compounds
US6147080A (en)	1996-12-18	2000-11-14	Vertex Pharmaceuticals Incorporated	Inhibitors of p38
US5945418A (en)	1996-12-18	1999-08-31	Vertex Pharmaceuticals Incorporated	Inhibitors of p38
CA2275796A1 (en)	1996-12-23	1998-07-02	Donald Joseph Phillip Pinto	Nitrogen containing heteroaromatics as factor xa inhibitors
US6087496A (en)	1998-05-22	2000-07-11	G. D. Searle & Co.	Substituted pyrazoles suitable as p38 kinase inhibitors
US5932576A (en)	1997-05-22	1999-08-03	G. D. Searle & Company	3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors
US6251914B1 (en)	1997-07-02	2001-06-26	Smithkline Beecham Corporation	Cycloalkyl substituted imidazoles
CN1158269C (zh)	1997-10-27	2004-07-21	阿古龙制药公司	作为cdk抑制剂的取代的4-氨基-噻唑-2-基化合物
PL344004A1 (en) *	1998-05-05	2001-09-10	Hoffmann La Roche	Pyrazole derivatives as p-38 map kinase inhibitors
US6316466B1 (en)	1998-05-05	2001-11-13	Syntex (U.S.A.) Llc	Pyrazole derivatives P-38 MAP kinase inhibitors
US6376527B1 (en)	1998-05-05	2002-04-23	Syntex (U.S.A.) Llc	Pyrazole derivatives-p38 map kinase inhibitors
US20020156114A1 (en)	1998-05-05	2002-10-24	Goldstein David Michael	Pyrazole derivatives - p38 MAP kinase inhibitors
US6130235A (en)	1998-05-22	2000-10-10	Scios Inc.	Compounds and methods to treat cardiac failure and other disorders
US6184226B1 (en)	1998-08-28	2001-02-06	Scios Inc.	Quinazoline derivatives as inhibitors of P-38 α
CA2342251A1 (en)	1998-08-28	2000-03-09	Scios Inc.	Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase
AU764479B2 (en)	1998-10-29	2003-08-21	Bristol-Myers Squibb Company	Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme
GB9906566D0 (en)	1999-03-23	1999-05-19	Zeneca Ltd	Chemical compounds
CA2366932C (en)	1999-04-15	2009-08-25	Bristol-Myers Squibb Company	Cyclic protein tyrosine kinase inhibitors
GB9924092D0 (en)	1999-10-13	1999-12-15	Zeneca Ltd	Pyrimidine derivatives
US6610697B1 (en)	1999-11-10	2003-08-26	Ortho-Mcneil Pharmaceutical, Inc.	Substituted 2-aryl-3-(heteroaryl)-imidazo[1,2-a]pyrimidines, and related pharmaceutical compositions and methods
WO2001056567A1 (en)	2000-02-04	2001-08-09	Novo Nordisk A/S	2,4-diaminothiazole derivatives and their use as glycogen synthase kinase-3 (gsk-3) inhibitors
WO2002024200A1 (en)	2000-09-21	2002-03-28	Bristol-Myers Squibb Company	Substituted azole derivatives as inhibitors of corticotropin releasing factor
AU3276002A (en)	2000-11-17	2002-05-27	Bristol Myers Squibb Co	Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
WO2002057101A2 (en)	2001-01-17	2002-07-25	Boyean Kim	Sun visor having office work apparatus
US6756374B2 (en)	2001-01-22	2004-06-29	Hoffmann-La Roche Inc.	Diaminothiazoles having antiproliferative activity
US7271181B2 (en)	2001-05-11	2007-09-18	Vertex Pharmaceuticals Incorporated	Inhibitors of p38
HN2002000156A (es)	2001-07-06	2003-11-27	Inc Agouron Pharmaceuticals	Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
GB0124941D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124931D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124932D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124928D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124936D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124933D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124934D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124938D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124939D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0217757D0 (en)	2002-07-31	2002-09-11	Glaxo Group Ltd	Novel compounds
JP2007517052A (ja) *	2003-12-23	2007-06-28	ノバルティスアクチエンゲゼルシャフト	二環式ヘテロ環式ｐ−３８キナーゼ阻害剤
JP2007084437A (ja)	2003-12-26	2007-04-05	Dai Ichi Seiyaku Co Ltd	アミノアルキルピラゾール誘導体

2004
- 2004-06-24 CN CN2004800180564A patent/CN1832928B/zh not_active Expired - Lifetime
- 2004-06-24 AT AT04777075T patent/ATE517872T1/de active
- 2004-06-24 ES ES10164367T patent/ES2393950T3/es not_active Expired - Lifetime
- 2004-06-24 KR KR1020057024679A patent/KR101120857B1/ko not_active Expired - Lifetime
- 2004-06-24 PL PL04777075T patent/PL1641764T3/pl unknown
- 2004-06-24 SI SI200431950T patent/SI2298743T1/sl unknown
- 2004-06-24 AU AU2004259662A patent/AU2004259662B2/en not_active Expired
- 2004-06-24 PL PL10164367T patent/PL2298743T3/pl unknown
- 2004-06-24 HR HR20110757T patent/HRP20110757T1/hr unknown
- 2004-06-24 CA CA2526455A patent/CA2526455C/en not_active Expired - Lifetime
- 2004-06-24 JP JP2006517650A patent/JP4838121B2/ja not_active Expired - Lifetime
- 2004-06-24 TW TW100114024A patent/TWI449696B/zh not_active IP Right Cessation
- 2004-06-24 WO PCT/US2004/020384 patent/WO2005009973A1/en not_active Ceased
- 2004-06-24 NZ NZ544230A patent/NZ544230A/en not_active IP Right Cessation
- 2004-06-24 DK DK04777075.5T patent/DK1641764T3/da active
- 2004-06-24 TW TW093118259A patent/TWI452035B/zh not_active IP Right Cessation
- 2004-06-24 PT PT101643674T patent/PT2298743E/pt unknown
- 2004-06-24 DK DK10164367.4T patent/DK2298743T3/da active
- 2004-06-24 PT PT04777075T patent/PT1641764E/pt unknown
- 2004-06-24 EP EP04777075A patent/EP1641764B1/en not_active Expired - Lifetime
- 2004-06-24 MX MXPA05013824A patent/MXPA05013824A/es active IP Right Grant
- 2004-06-24 SI SI200431766T patent/SI1641764T1/sl unknown
- 2004-06-24 EP EP10164367A patent/EP2298743B1/en not_active Expired - Lifetime
- 2004-06-24 BR BRPI0411825A patent/BRPI0411825B8/pt not_active IP Right Cessation
- 2004-06-25 MY MYPI20042496A patent/MY158162A/en unknown
- 2004-06-25 US US10/877,534 patent/US7863314B2/en not_active Expired - Lifetime
2005
- 2005-11-24 IL IL172182A patent/IL172182A/en active IP Right Grant
- 2005-12-08 EC EC2005006206A patent/ECSP056206A/es unknown
- 2005-12-21 MA MA28678A patent/MA27888A1/fr unknown
2006
- 2006-01-23 IS IS8255A patent/IS2916B/is unknown
- 2006-01-26 NO NO20060424A patent/NO334947B1/no unknown
2010
- 2010-11-19 US US12/950,649 patent/US8242117B2/en not_active Expired - Lifetime
2011
- 2011-10-27 CY CY20111101022T patent/CY1111985T1/el unknown
2012
- 2012-02-07 EC ECSP12006206 patent/ECSP12006206A/es unknown
- 2012-06-22 US US13/530,919 patent/US8410160B2/en not_active Expired - Fee Related
- 2012-11-08 HR HRP20120900TT patent/HRP20120900T1/hr unknown
- 2012-11-08 CY CY20121101064T patent/CY1113313T1/el unknown
2013
- 2013-02-25 US US13/775,963 patent/US8580838B2/en not_active Expired - Fee Related
2014
- 2014-01-28 IS IS9037A patent/IS2984B/is unknown

Also Published As

Publication number	Publication date
US7863314B2 (en)	2011-01-04
ECSP12006206A (es)	2012-03-30
PL2298743T3 (pl)	2013-02-28
US20110071152A1 (en)	2011-03-24
BRPI0411825B8 (pt)	2021-05-25
PL1641764T3 (pl)	2011-12-30
ES2393950T3 (es)	2013-01-02
EP1641764B1 (en)	2011-07-27
CN1832928A (zh)	2006-09-13
US8242117B2 (en)	2012-08-14
BRPI0411825B1 (pt)	2018-11-06
TWI449696B (zh)	2014-08-21
IS2984B (is)	2017-09-15
AU2004259662B2 (en)	2008-08-07
DK2298743T3 (da)	2012-11-26
JP4838121B2 (ja)	2011-12-14
CA2526455A1 (en)	2005-02-03
CY1111985T1 (el)	2015-11-04
TWI452035B (zh)	2014-09-11
CN1832928B (zh)	2012-07-04
BRPI0411825A (pt)	2006-08-08
EP2298743B1 (en)	2012-08-22
HK1088895A1 (en)	2006-11-17
US8410160B2 (en)	2013-04-02
EP1641764A1 (en)	2006-04-05
US20130172352A1 (en)	2013-07-04
HRP20110757T1 (hr)	2011-11-30
KR101120857B1 (ko)	2012-04-12
US20120264801A1 (en)	2012-10-18
TW201125854A (en)	2011-08-01
HK1149764A1 (en)	2011-10-14
IS2916B (is)	2014-12-15
IL172182A (en)	2014-07-31
TW200510328A (en)	2005-03-16
IS8255A (is)	2006-01-23
CY1113313T1 (el)	2016-04-13
JP2007521278A (ja)	2007-08-02
HRP20120900T1 (hr)	2012-11-30
US20050049288A1 (en)	2005-03-03
NO20060424L (no)	2006-03-15
MY158162A (en)	2016-09-15
PT2298743E (pt)	2012-12-04
SI1641764T1 (sl)	2011-11-30
KR20060024813A (ko)	2006-03-17
IS9037A (is)	2014-01-28
NO334947B1 (no)	2014-08-04
CA2526455C (en)	2012-10-09
ECSP056206A (es)	2006-04-19
SI2298743T1 (sl)	2012-12-31
WO2005009973A1 (en)	2005-02-03
NZ544230A (en)	2009-07-31
ATE517872T1 (de)	2011-08-15
PT1641764E (pt)	2011-10-27
AU2004259662A1 (en)	2005-02-03
US8580838B2 (en)	2013-11-12
MXPA05013824A (es)	2006-02-28
MA27888A1 (fr)	2006-05-02
EP2298743A1 (en)	2011-03-23

Publication	Publication Date	Title
DK2298743T3 (da)	2012-11-26	p38-Kinaseinhibitorer på grundlag af en 5-leddet heterocyclisk ring
ATE439837T1 (de)	2009-09-15	5-gliedrige heterocyclische p-38 inhibitoren
ATE457313T1 (de)	2010-02-15	Bicyclische heterocyclische p-38-kinase- inhibitoren
MX2007000036A (es)	2007-05-18	Antagonistas del receptor 2 de citocina quimioatrayente de sales cuaternarias.
ATE517896T1 (de)	2011-08-15	P38-kinase-inhibitoren
NZ548954A (en)	2009-07-31	Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
EP1689406A4 (en)	2007-01-17	HETEROCYCLIC INHIBITORS OF MEK AND METHOD FOR THEIR APPLICATION
CY1109529T1 (el)	2014-08-13	2-(αμινο-υποκατεστημενες)-4-αρυλο πυραμιδινες και σχετικες ενωσεις που χρησιμευουν στην αγωγη φλεγμονωδων νοσηματων
DE60322423D1 (de)	2008-09-04	Pyrrolidin- und azetidinverbindungen alsccr5-antagonisten
NO20054726L (no)	2005-12-08	2, 4-di(fenylamino)pyrimidiner anvendelige ved behandling av neoplastiske sykdommer, inflammasjons- og immunsystemforstyrrelser
WO2004072062A3 (en)	2004-11-04	Indolylmaleimide derivatives
DK1492773T3 (da)	2009-04-14	4-(Heterocyclyl)-benzensulfoximin-forbindelser til behandling af inflammation
NO20065762L (no)	2007-02-12	Prodroger av pyrrolypyrimidin-ERK-proteinkinaseinhibitorer.
NO20055563L (no)	2005-11-24	Midler for behandlingen av lavere abdominale lidelser
DK1309322T3 (da)	2006-10-23	Anvendelse af 3-benzoylphenyleddikesyrederivater til behandling af retinale lidelser
DE602004007284D1 (de)	2007-08-09	Pyrimidine als inhibitoren von phosphoinositid-3-kinasen (pi3k)
TNSN05307A1 (en)	2007-07-10	5-membered heterocycle-based p38 kinase inhibitors